PMV Pharmaceuticals Inc PMVP
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-25 |
| Shares Out. | 53,330,000 |
| Website | pmvpharma.com/ ↗ |
| Phone | 13026365400 |
| Employees | 54 |
| Net Income | -$18.0M |
| Free Cash Flow | -$75.0M |
| Total Assets | $96.6M |
| Total Liabilities | $8.6M |
| Equity | $88.0M |
About PMV Pharmaceuticals Inc
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
PMV Pharmaceuticals Inc is a publicly traded company under the ticker symbol PMVP on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)